Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2624855 | 0.93 | ALOX5 (0.33) | ALOX5 | |
| SCHEMBL16900172 | 0.93 | ALOX5 (0.33) | ALOX5 | |
| SCHEMBL13746651 | 0.90 | APP (0.35) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL29406722 | 0.90 | APP (0.35) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL22863326 | 0.90 | APP (0.35) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL15744228 | 0.90 | APP (0.35) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL9880208 | 0.90 | APP (0.35) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL13663953 | 0.89 | APP (0.36) | APPALOX5NR1H4ABCG2BACE1 | |
| SCHEMBL23941477 | 0.88 | ALOX5 (0.37) | APPALOX5NR1H4BACE1PTPN1 | |
| SCHEMBL22863355 | 0.88 | ALOX5 (0.37) | APPALOX5NR1H4BACE1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-06-13 | — | — | US | claimed |
| CN-117164597-B | SMTP-0 synthesis method | 深圳创元生物医药科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| EP-4252752-A1 | DRUG FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE, AND METHOD FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE USING SAID DRUG | Biogen MA Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| CN-116761600-A | Medicament for treating or preventing cerebral hemorrhage and method for treating or preventing cerebral hemorrhage using the same | 渤健马萨诸塞州股份有限公司 | 2023-09-15 | — | — | CN | claimed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | claimed |
| CN-114126711-A | Medicament and method for treating or preventing diabetic complications using the same | 学校法人昭和大学 | 2022-03-01 | — | — | CN | claimed |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2025-10-28 | — | — | US | disclosed |
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | SHOWA MEDICAL UNIVERSITY (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | SHOWA UNIVERSITY (JP) | 2024-11-12 | — | — | US | disclosed |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | CORXEL PHARMACEUTICALS HONG KONG LIMITED (CN) | 2024-06-13 | — | — | US | disclosed |
| CN-117164597-B | SMTP-0 synthesis method | 深圳创元生物医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117164597-B | SMTP-0 synthesis method | 深圳创元生物医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117164597-B | SMTP-0 synthesis method | 深圳创元生物医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111936134-B | Pharmaceutical agent and method for treating or preventing kidney disease using the same | 学校法人昭和大学 | 2023-12-08 | — | — | CN | disclosed |
| EP-4252752-A1 | DRUG FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE, AND METHOD FOR TREATMENT OR PREVENTION OF CEREBRAL HEMORRHAGE USING SAID DRUG | Biogen MA Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116761600-A | Medicament for treating or preventing cerebral hemorrhage and method for treating or preventing cerebral hemorrhage using the same | 渤健马萨诸塞州股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| US-RE49351-E1 | Cytoprotective agent | BIOGEN MA INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11440920-B2 | Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method | SHOWA UNIVERSITY (JP) | 2022-09-13 | — | — | US | disclosed |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SHOWA UNIVERSITY (JP) | 2022-07-14 | — | — | US | disclosed |
| CN-114126711-A | Medicament and method for treating or preventing diabetic complications using the same | 学校法人昭和大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099427-A1 | Drug and Method of Treating or Preventing Renal Disease Using Drug | REN, ATP6V1B1, SLC10A1 | APP 2305/4885ALOX5 117/4885NR1H4 342/4885 |
| US-12138244-B2 | Drug and method of treating or preventing renal disease using drug | REN, ATP6V1B1, SLC10A1 | APP 2305/4885ALOX5 117/4885NR1H4 342/4885 |
| US-12453718-B2 | Drug for treating or preventing cerebral hemorrhage, and method for treating or preventing cerebral hemorrhage using the drug | PROC, FABP7, SERPINC1 | APP 592/4885ALOX5 285/4885NR1H4 2319/4885 |
| US-20220218664-A1 | DRUG AND METHOD FOR TREATING OR PREVENTING COMPLICATIONS FROM DIABETES, USING SAID DRUG | SLC5A2, SLC5A1, IAPP | APP 728/4885ALOX5 71/4885NR1H4 493/4885 |
| US-20240189280-A1 | DRUG FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE, AND METHOD FOR TREATING OR PREVENTING CEREBRAL HEMORRHAGE USING THE DRUG | PROC, FABP7, SERPINC1 | APP 592/4885ALOX5 285/4885NR1H4 2319/4885 |
| US-11440920-B2 | Chemical method of producing SMTP groups or SMTP-7 and intermediates used in the method | SMS, TST, TES | APP 1966/4885ALOX5 4649/4885NR1H4 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.